Compare Recursion Pharmaceuticals Inc (RXRX) vs S&P500 ETF (SPY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs S&P500 ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $3.34 (market cap $1.78B), while S&P500 ETF trades at $771.7. The key difference: S&P500 ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | SPY | |
|---|---|---|
Market Cap | $1.78B | — |
Sector | Health | — |
52-Week High | $6.79 | $773.22 |
52-Week Low | $2.84 | $631.99 |
Enterprise Value | $1.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.
Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.
SPY, the SPDR S&P 500 ETF, trades at $773.22, up 0.6% with a bullish technical signal from moving averages. The ETF shows strong institutional interest and benefits from robust S&P 500 earnings growth, though RSI indicates short-term overbought conditions. A dividend of $1.90 is scheduled for July 2026, adding income appeal.
Outlook remains positive with JPMorgan raising its S&P 500 target to 8,000, driven by AI-driven earnings. Risks include high valuations and potential pullbacks from overbought levels. Investors should weigh long-term growth against near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About S&P500 ETF
The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on SPY →
